Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series by Wouters, T. et al.
Case Reports in Women's Health 22 (2019) e00105
Contents lists available at ScienceDirect
Case Reports in Women's Health
j ourna l homepage: www.e lsev ie r .com/ locate /c rwhSystemic adverse events in imiquimod use for cervical intraepithelial
neoplasia – A case seriesTirza Wouters a,⁎, Natasja Hendriks b, Margot Koeneman b, Arnold-Jan Kruse b, Anna van de Sande c,
Heleen J. van Beekhuizen c, Kees G. Gerestein d, Ruud L.M. Bekkers a, Jurgen M.J. Piek a
a Department of Obstetrics and Gynaecology, Catharina Hospital, Eindhoven, the Netherlands
b Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, the Netherlands
c Department of Obstetrics and Gynaecology, Erasmus Medical Centre, Rotterdam, the Netherlands
d Department of Obstetrics and Gynaecology, University Medical Centre Utrecht, Utrecht, the Netherlands⁎ Corresponding author at: Catharina Hospital, D
Gynaecology, Michelangelolaan 2, 5623 EJ Eindhoven, the
E-mail address: tirza.wouters@catharinaziekenhuis.nla b s t r a c ta r t i c l e i n f oArticle history:
Received 3 January 2019
Received in revised form 25 February 2019
Accepted 26 February 2019Treatment for cervical intraepithelial neoplasia (CIN) often consists of an excisional procedure. However, less
invasive treatment methods have been explored, such as topical treatment with imiquimod cream. Imiquimod
has been proven to be effective in the regression of vulvar intraepithelial neoplasia (VIN) and vaginal
intraepithelial neoplasia (VAIN). Previous studies have investigated the effect of imiquimod in CIN and showed
well tolerated adverse effects. During a current study in the Netherlands, a number of adverse events have
occurred. This case series presents a selection of these. Gynaecologists should be aware of the possible adverse
effects of topical treatment with imiquimod cream.
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Cervical intraepithelial neoplasia (CIN) is a premalignancy.
Treatment often consists of an excisional procedure with possibly
a negative impact on subsequent pregnancies, as it is associated
with a significantly higher risk of miscarriage [1]. To prevent these
adverse effects, less invasive treatment methods have been ex-
plored. A possible non-invasive therapy for CIN is a toll-like receptor
(TLR) 7 agonist: imiquimod.
Imiquimod cream has been proven to be effective in the regression
of vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neo-
plasia (VAIN) [2,3]. Both VIN and VAIN are HPV-related neoplasia and
the pathophysiology is comparable to CIN. Previous studies have inves-
tigated the effect of imiquimod in CIN and showed the adverse effects to
be well-tolerated [4,5]. Currently, a non-randomised study comparing
the effectiveness of imiquimod treatment with large loop excision of
the transformation zone (LLETZ) is being performed in the Netherlands
(TOPIC-3) [6]. The patients were instructed to administer one sachet
containing 12,5 mg of 5% imiquimod with a vaginal applicator three
times weekly intravaginally. During this study, a number of adverseepartment of Obstetrics and
Netherlands.
(T. Wouters).events have occurred, in some cases severe enough for patients to dis-
continue treatment with imiquimod.
The purpose of this case series is to present the serious adverse
events in patients who received imiquimod 5% cream intravaginally
for cervical intraepithelial neoplasia (CIN 2–3). Gynaecologists should
be aware of these adverse effects. In addition, a summary of prior re-
search on adverse effects in CIN is provided. We obtained medical ethi-
cal approval as well as written consent from the patients described.
2. Patient Series
2.1. Case 1
A 79-year-old womanwith myocardial infarction and anxiety disor-
der in her medical history was seen at the outpatient clinic with post-
menopausal bleeding. During the workup, a cervical smear revealed
atypical squamous metaplasia. Colposcopic and histological examina-
tion revealed a high-grade squamous intraepithelial lesion (HSIL). In
preference to surgical intervention, the patient chose the imiquimod
treatment. After three vaginal applications, with the last application
4 days earlier, the patient was hospitalised with general malaise,
persisting nausea, mild diarrhoea, asymptomatic hyponatremia (Na+
126 mmol/L) and leukopenia (2.5/nL). Her C-reactive protein (CRP)
level was b6.0 mg/L and her temperature was between 36.5 and 37 °C
Table 1
Summary of three cases with adverse events.
Case Age Bethesda
system
Number of
imiquimod
applications
Adverse effects Serious
adverse events
1 79 LSIL 3 − Malaise
− Persisting nausea
− Mild diarrhoea
− Asymptomatic
hyponatremia
− Leukopenia
Hospitalisation
2 51 HSIL 18 − Spontaneous
headache
− Light-headedness
Hospitalisation
3 45 HSIL 12 − Headache
− Abdominal pain
− Nausea
− Fatigue
− Fever
− Erosion of the
cornea
Corneal
erosion
LSIL = low-graded squamous intraepithelial lesion; HSIL = high-grade squamous
intraepithelial lesion.
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patient. The imiquimod creamwas discontinued as it was hypothesised
that the creamwas the cause of the clinical complaints. After three days,
the patient was discharged fully recovered. She did not restart the
imiquimod treatment.
2.2. Case 2
A 51-year-old woman with post-traumatic stress disorder, high
blood pressure, hypercholesterolemia and spinal stenosis C5–C6 in her
medical history was seen at the outpatient clinic with persistent vagi-
nal bleeding after IUD insertion. During the workup, a cervical smear
revealed a mild–moderate dysplasia. Colposcopic and histological
examination showed HSIL. The patient did not want to experience the
excisional procedure and therefore chose the imiquimod treatment.
After 6 weeks of vaginal application of imiquimod, the patient was
hospitalisedwith spontaneous headache and light-headedness. Her lab-
oratory results showed a CRP of b6.0 mg/L, leukocytes of 8.2/nL and
D-dimer of 0.32mg/L. Imaging techniques and examination of the cere-
bral liquor did not explain her symptoms. No local effects were men-
tioned by the patient. The imiquimod treatment was discontinued.
The patient was released from hospital the next day as the symptoms
disappeared during the hospitalisation.
2.3. Case 3
A 45-year-old woman with a herpes simplex virus infection, breast
reduction and caesarean section in her medical history presented
at the outpatient clinic with an abnormal cervical smear detected
by the national screening programme for cervical premalignancies.Table 2
Studies reporting systemic and local adverse effects in imiquimod treatment for cervical intrae
Study Study
design
Treatment Adverse effects
Systemic adverse effects
Head-ache Fever Fatigue
Grimm et al. [8] RCT Imiquimod group n = 30 25 (83) 29 (97)
Placebo group n= 29 6 (21) 12 (34)
Pachman et al. [9] PS Imiquimod n= 28 7 (25) 5 (18) 13 (46
ST n = 28 0 (0) 0 (0) 0 (0)
Lin et al. [10] RS Entire cohort n= 72 – 3 (4) 2 (3)
RCT = randomised controlled trial; PS = prospective study; RS = retrospective study; ST = sColposcopic and histological examination revealed HSIL and the patient
chose the imiquimod treatment to prevent the excisional procedure.
After 4weeks of vaginal application of imiquimod, the gynaecologist de-
cided to stop the treatment due to systemic adverse effects: headache,
abdominal pain, nausea, fatigue, a temperature of 38.9 °C and a sponta-
neous erosion of the cornea. The patient reported vaginal discharge and
vaginal bleeding a week before the appearance of the systemic effects.
No laboratory tests were performed. Cultures were negative for micro-
organisms that could explain the erosion of the cornea. As it was
hypothesised that the cream could be the cause of the complaints, the
treatment was discontinued. Within 45 days, all complaints subsided
and the patient recovered from the erosion of the cornea.3. Discussion
Wedescribe three cases of adverse events inwomen treated for HSIL
with imiquimod, summarized in Table 1. However, in none of the pa-
tients were these adverse effects proven to be caused by imiquimod.
The symptoms all disappeared after discontinuation of imiquimod.
In a previous review, DeWitte et al. showed a higher rate of adverse ef-
fects in imiquimod use comparedwith placebo; however, these adverse
effects were less severe than in our study [7]. Themost common and se-
vere local and systemic effects reported in literature are summarized in
Table 2.
Adverse effects of imiquimod treatment of H/LSIL lesions were pre-
viously reported by three authors. Firstly, the RCT performed by
Grimm et al. established local and systemic adverse effects [4]. The
authors concluded that the treatment was well tolerated without
high-grade adverse effects. Vaginal suppositories were used for the ap-
plication of the imiquimod cream by the patients themselves. Pachman
et al. studied the cervical application of imiquimod [8]. A near syncopal
event in one patient was described. However, this patient was not
hospitalised and she continued treatment. The 50 mg of 5% imiquimod
oil-in-water cream was applied directly to the ectocervix by the re-
search nurse. A retrospective study was carried out by Lin et al.5 In
their study, no patient discontinued the treatment due to adverse ef-
fects. In this study, the patients were instructed to apply 250 mg of 5%
imiquimod cream using their fingers.
Based on these studies, the adverse effects of imiquimod seem well
tolerated. The most common systemic adverse effects described in
these studies were: headache, fever and/or fatigue and myalgia. With
the exception ofmyalgia, these systemic adverse effects were also expe-
rienced by the patients described in our case series. However, general
malaise, persisting nausea, mild diarrhoea, asymptomatic hyponatr-
emia, leukopenia, light-headedness, abdominal pain, nausea and a spon-
taneous erosion of the cornea were not mentioned before.
The systemic adverse effects can be explained by the mechanism
of action of the cream. Schön et al. detail how the major effect is
caused by the agonistic activity towards TLR 7 and 8 and nuclear
factor-kappa B (NF-kappa B) [9]. This activation induces the upregu-
lation of pro-inflammatory cytokines and chemokines. A study perfo-
rmed by Nerurkar et al. established significant upregulation ofpithelial neoplasia.
Serious
adverse
events
Local adverse effects
Myalgia Vaginal
discharge
Vaginal
bleeding
Vulvar
pruritus
Vulvar
pain
Vaginal
edema
23 (77) – – 28 (93) 16 (53) No
3 (10) 11 (38) 3 (10)
) 15 (54) 9 (32) 1 (4) – – No
0 (0) 0 (0) 0 (0)
1 (2) 7 (10) – 3 (4) 2 (3) – No
tandard treatment.
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peripheral organs in mice exposed to imiquimod. Upregulation was
detected in skin, liver, lungs and the brain [10]. An increase in cyto-
kines and chemokines leads to activation of the T-helper (Th1) anti-
tumoral cellular immune response. Therefore, it could well be that
the systemic adverse effects were caused by the peripheral Th1 im-
mune response induced by the imiquimod cream.
It could be argued that the patients described in the present case
series should not have started the imiquimod treatment at all. The
non-invasive treatment with imiquimod was initially developed to
decrease the possibility of the negative impacts on subsequent preg-
nancies in women with a wish still to have children [11]. Women
with no intention to become pregnant do not have to weigh the pos-
sible negative impacts and they should be advised to weigh the
treatment and the adverse effects carefully. On the other hand, pa-
tients were allowed to choose a treatment arm in this study, for ex-
ample to prevent LLETZ under general anaesthesia. Therefore, the
imiquimod treatment in the described cases is justified by the
patient's own choice of treatment.
Based on the primary studies, the adverse effects in imiquimod
treatment for H/LSIL were well tolerated. However, during the current
TOPIC-3 study, we witnessed two serious adverse events and mild/
moderate adverse effects that could be due to imiquimod use. With
this case series, we draw attention to the possibility of serious adverse
events in imiquimod treatment, which are generally reversible. Moni-
toring patients during imiquimod use could reveal whether systemic
adverse effects are more frequent in imiquimod users.
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